





Kathleen M. Sakamoto

Shelagh Galligan Professor in the School of Medicine

Pediatrics - Hematology & Oncology

 NIH Biosketch available Online

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Pediatric Hematology/Oncology**

725 Welch Rd MC 5913

Palo Alto, CA 94304

Tel (650) 497-8953

Fax (650) 497-8101

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Dept. of Pediatrics - Administrative Associate

Email daisy@stanford.edu

Tel 3108252219

Bio

BIO

Dr. Sakamoto received her B.A. in Biology from Williams College and her M.D. from the University of Cincinnati. She was a pediatric resident and hematology/oncology fellow at Children's Hospital Los Angeles. Dr. Sakamoto was a research fellow at UCLA and then was a faculty member at UCLA in the Department of Pediatrics, Division of Hematology/Oncology for over 20 years. She received her Ph.D. in Biology from the California Institute of Technology. Dr. Sakamoto was the Division Chief of Pediatric Hematology/Oncology at UCLA for six years and was the Vice-Chair of Research in the Department of Pediatrics; co-Associate Director of the Signal Transduction Program Area of the UCLA Jonsson Comprehensive Cancer Center, and co-Chair of the UCLA Clinical and Translational Science Institute, Committee for Maternal, Child, and Adolescent Health. From 2011-2014, she was the Division Chief of Pediatric Hematology/Oncology/Stem Cell Transplant/Cancer Biology at Lucile Packard Children's Hospital at Stanford. Dr. Sakamoto was the Fellowship Program Director and is the P.I. of an NIH T32 training grant at Stanford. Currently, she is a member of the Child Health Research Institute Executive Committee at Stanford University and the Academic Promotion Committee for Stanford School of Medicine.

Dr. Sakamoto's research has focused on signaling pathways and gene regulation in normal and aberrant hematopoiesis, including leukemia and bone marrow failure syndromes. She is specifically interested in targeted therapies for leukemia and other types of pediatric cancers. Dr. Sakamoto has been funded by the National Institutes of Health for over 20 years. She currently holds the Shelagh Galligan Endowed Professorship and has received awards from the American Cancer Society, Leukemia & Lymphoma Society, Bear Necessities, and CDMRP(DOD). She has been a standing and ad hoc member of National Institutes of Health grant review committees for the past 15 years. She is Chair of the Bear Necessities Scientific Review Committee. She is currently developing novel therapies to target CREB for the treatment of acute leukemia. Promising small molecule compounds that are effective in the lab and nontoxic will be tested and optimized to take to the clinic for patients with relapsed leukemia. This will provide novel approaches to treat leukemia in children.

CLINICAL FOCUS

- Pediatric Hematology-Oncology
- Leukemia

ACADEMIC APPOINTMENTS

- Professor, Pediatrics - Hematology & Oncology

- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute
- Faculty Fellow, Stanford ChEM-H

ADMINISTRATIVE APPOINTMENTS

- Fellowship Program Director, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, (2011-2013)
- Chief, Division of Pediatric Hematology/Oncology/Stem Cell Transplantation/Cancer Biology, Bass Cancer Center, Lucile Packard Children's Hospital, (2011-2014)

HONORS AND AWARDS

- Victor E. Stork Award, Children's Hospital of Los Angeles (1988)
- STOP Cancer Career Development award, UCLA Jonsson Comprehensive Cancer Center (1992)
- Young Investigator Award, American Society of Pediatric Hematology/Oncology (1994)
- Junior Faculty Ross Research Award, Western Society for Pediatric Research (1996)
- Gift of Hope Award, Pediatric Cancer Research Foundation (2008)
- Fernbach Distinguished Visiting Professor Lectureship, Texas Children's Cancer Center (2009)
- Outstanding advances in cancer research award, Mendiburu Magic Foundation (2010)
- Brett Ely Visiting Professor in Pediatric Oncology, University of Colorado and Children's Hospital Denver (2011)
- Chair, Myeloid Biology Subcommittee, American Society of Hematology (2011)
- Standing Member, NIDDK-D Study Section for Training Grants and K awards (2011-2016)
- Shelagh Galligan Endowed Chair, Stanford University (2012)
- Jason Bennette Memorial Lectureship, Cohen Children's Hospital, Long Island, NY (2013)
- Steven Rosen Endowed Lectureship, Northwestern University School of Medicine (2015)
- Pediatric Cancer Research Foundation Memorial Lecture Honoree, Pediatric Cancer Research Foundation (2016)
- Specialized Training and Research (STAR) Program Alumni Achievement Award, UCLA (2019)
- NIDDK Council Member, National Institutes of Health (2020-2023)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Scientific Advisory Board, St. Baldrick's Foundation (2016 - present)
- Chair, Physician Scientist Special interest Group, American Society of Pediatric Hematology/Oncology (2017 - present)
- Chair, Scientific Review Committee, Bear Necessities Foundation (2017 - present)
- Grant Review Committee, Scholar Awards, American Society of Hematology (2017 - present)
- Scientific Advisory Committee, Alex's Lemonade Stand Foundation (2017 - present)

PROFESSIONAL EDUCATION

- Fellowship: Children's Hospital Los Angeles (1991) CA
- Board Certification: Pediatrics, American Board of Pediatrics (1989)
- Residency: Children's Hospital Los Angeles (1988) CA
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (1992)
- Medical Education: University of Cincinnati College of Medicine (1985) OH
- B.A., Williams College, Biology (1979)

- M.D., University of Cincinnati College of Medicine , Medicine (1985)
- Ph.D., California Institute of Technology , Biology (2004)
- Internship and Residency, Children's Hospital Los Angeles , Pediatrics (1988)
- Fellowship, Children's Hospital Los Angeles , Pediatric Hematology/Oncology (1991)
- Postdoctoral Fellowship, UCLA School of Medicine , Hematopoietic growth factors and signal transduction (1992)

PATENTS

- Kathleen Sakamoto. "United States Patent CIT3284 Proteolysis Targeting Chimeric Pharmaceutical", California Institute of Technology
- Kathleen Sakamoto. "United States Patent STAN-1280WO (S15-428) Inhibitors of CREB:CBP Interaction for Treatment of Acute Myeloid Leukemia", Stanford University, Mar 10, 2017

LINKS

- My Lab Site: <http://sakamolab.com/>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Transcriptional regulation in leukemogenesis

CREB is a leucine zipper transcription factor that controls cell proliferation, differentiation, and survival. CREB is overexpressed in bone marrow cells from the majority of patients with acute lymphoblastic and myeloid leukemia. CREB transgenic mice develop myeloproliferative disease, i.e. preleukemia, but not acute leukemia. Therefore, CREB is an oncogene that requires additional mutations. We are studying other cooperating oncogenes that contribute to leukemogenesis. In addition, downstream target genes are being explored. We are also studying a small molecule inhibitor of CREB for the treatment of acute leukemia.

Targeted therapy for leukemia and other cancers

In collaboration with pharmaceutical companies, we are testing novel compounds to target specific signaling molecules in AML. Among the small molecules being studied in vitro and in vivo are inhibitors of receptor tyrosine kinases, aurora kinases, and anti-apoptotic proteins. Mechanistic pathways are being investigated.

Protacs are chimeric molecules to target cancer causing proteins for ubiquitination and degradation. We have demonstrated the feasibility of using this approach in prostate and breast cancer cell lines to target the androgen and estrogen receptors for ubiquitination and degradation, resulting in apoptosis. Approaches are being developed to design Protacs for clinical trials in humans.

Signaling Pathways in bone marrow failure syndromes

Defects in ribosome biogenesis have been associated with specific bone marrow failure syndromes, such as Diamond Blackfan Anemia. We are studying the signaling pathways that are altered by deficiency in specific ribosomal protein subunits. Zebrafish, mouse, and human cells are being used to characterize p53-dependent and #independent pathways mediating aberrant erythropoiesis and increased risk of cancer in these patients. Novel drugs are being tested.

CLINICAL TRIALS

- Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies, Recruiting
- Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed < 6 Months Post All-HSCT., Not Recruiting
- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia, Not Recruiting

- Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients, Not Recruiting

Teaching

COURSES

2019-20

- Pediatric Nonmalignant Hematology and Stem Cell Biology: PATH 290 (Aut)

2018-19

- Cancer Biology Journal Club: CBIO 280 (Win)

2017-18

- Pediatric Nonmalignant Hematology and Stem Cell Biology: PATH 290 (Aut)

STANFORD ADVISEES

Doctoral Dissertation Reader (AC)

Gerald Tiu

Postdoctoral Faculty Sponsor

Chris Severyn, Mark Wilkes

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)

Publications

PUBLICATIONS

- **MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-beta pathways.** *Blood advances*
Youn, M., Huang, H., Chen, C., Kam, S., Wilkes, M. C., Chae, H., Sridhar, K. J., Greenberg, P. L., Glader, B., Narla, A., Lin, S., Sakamoto, K. M.
2019; 3 (18): 2751–63
- **Innate immune system activation in zebrafish and cellular models of Diamond Blackfan Anemia** *SCIENTIFIC REPORTS*
Danilova, N., Wilkes, M., Bibikova, E., Youn, M., Sakamoto, K. M., Lin, S.
2018; 8: 5165
- **Nicosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways** *ONCOTARGET*
Chae, H., Cox, N., Dahl, G. V., Lacayo, N. J., Davis, K. L., Capolicchio, S., Smith, M., Sakamoto, K. M.
2018; 9 (4): 4301–17
- **Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.** *Leukemia*
Mitton, B., Chae, H., Hsu, K., Dutta, R., Aldana-Masangkay, G., FERRARI, R., Davis, K., Tiu, B. C., Kaul, A., Lacayo, N., Dahl, G., Xie, F., Li, et al
2016
- **Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters.** *Oncotarget*
Mitton, B., Hsu, K., Dutta, R., Tiu, B. C., Cox, N., McLure, K. G., Chae, H., Smith, M., Eklund, E. A., Solow-Cordero, D. E., Sakamoto, K. M.
2016; 7 (8): 8653-8662
- **Biology of the bone marrow microenvironment and myelodysplastic syndromes.** *Molecular genetics and metabolism*
Rankin, E. B., Narla, A., Park, J. K., Lin, S., Sakamoto, K. M.
2015; 116 (1-2): 24-28
- **Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA** *LEUKEMIA*
Chae, H., Mitton, B., Lacayo, N. J., Sakamoto, K. M.
2015; 29 (6): 1379-1389

- **Targeting novel signaling pathways for resistant acute myeloid leukemia** *MOLECULAR GENETICS AND METABOLISM*
Sakamoto, K. M., Grant, S., Saleiro, D., Crispino, J. D., Hijjiya, N., Giles, F., Plataniias, L., Eklund, E. A.
2015; 114 (3): 397-402
- **The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3 beta-Dependent Pathway** *MOLECULAR CANCER THERAPEUTICS*
Hernandez-Davies, J. E., Zape, J. P., Landaw, E. M., Tan, X., Presnell, A., Griffith, D., Heinrich, M. C., Glaser, K. B., Sakamoto, K. M.
2011; 10 (6): 949-959
- **CREB and leukemogenesis.** *Critical reviews in oncogenesis*
Cho, E., Mitton, B., Sakamoto, K. M.
2011; 16 (1-2): 37-46
- **Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family** *BLOOD*
Danilova, N., Sakamoto, K. M., Lin, S.
2008; 112 (13): 5228-5237
- **The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia** *CANCER CELL*
Shankar, D. B., Cheng, J. C., Kinjo, K., Federman, N., Moore, T. B., Gill, A., Rao, N. P., Landaw, E. M., Sakamoto, K. M.
2005; 7 (4): 351-362
- **Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain** *SCIENCE*
Verma, R., Peters, N. R., D'onofrio, M., Tochtrop, G. P., Sakamoto, K. M., Varadan, R., Zhang, M. S., Coffino, P., Fushman, D., Deshaies, R. J., King, R. W.
2004; 306 (5693): 117-120
- **Development of PROTACS to target cancer-promoting proteins for ubiquitination and degradation** *MOLECULAR & CELLULAR PROTEOMICS*
Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., Deshaies, R. J.
2003; 2 (12): 1350-1358
- **PROTACS: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., Deshaies, R. J.
2001; 98 (15): 8554-8559
- **Net1 stimulates RNA polymerase I transcription and regulates nucleolar structure independently of controlling mitotic exit** *MOLECULAR CELL*
Shou, W. Y., Sakamoto, K. M., Keener, J., Morimoto, K. W., Traverso, E. E., Azzam, R., Hoppe, G. J., Feldman, R. M., DeModena, J., Moazed, D., Charbonneau, H., Nomura, M., Deshaies, et al
2001; 8 (1): 45-55
- **SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway.** *Bioorganic & medicinal chemistry letters*
Chae, H. D., Cox, N., Capolicchio, S., Lee, J. W., Horikoshi, N., Kam, S., Ng, A. A., Edwards, J., Butler, T. L., Chan, J., Lee, Y., Potter, G., Capece, et al
2019
- **Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells**
Chae, H., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Huang, M., Sumarsono, et al
AMER SOC HEMATOLOGY.2018
- **Chromatin Organization By SATB1 Regulates HSP70 Induction in Early Erythropoiesis and Lost in Diamond Blackfan Anemia**
Wilkes, M. C., Takasaki, K., Youn, M., Chae, H., Narla, A., Sakamoto, K. M.
AMER SOC HEMATOLOGY.2018
- **MMP9 Inhibition Rescues the Erythroid Defect in RPS14-Deficient Del(5q) MDS Models**
Youn, M., Huang, H., Chen, C., Kam, S., Wilkes, M. C., Chae, H., Narla, A., Lin, S., Sakamoto, K. M.
AMER SOC HEMATOLOGY.2018
- **Pharmacological Inhibition of Nlk (Nemo-like Kinase) Rescues Erythropoietic Defects in Pre-Clinical Models of Diamond Blackfan Anemia**
Wilkes, M. C., Chen, J., Siva, K., Veretti, G., Dever, D. P., Youn, M., Chae, H., Mercado, J. D., Saxena, M., Narla, A., Glader, B., Porteus, M., Repellin, et al

AMER SOC HEMATOLOGY.2018

- **Chromatin Remodeling Therapy and Capizzi Methotrexate in Treatment-Related MDS/AML**
Aftandilian, C., Sakamoto, K. M., Davis, K. L., Dahl, G., Lacayo, N. J.
AMER SOC HEMATOLOGY.2018
- **CBP modulates sensitivity to dasatinib in pre-BCR+ acute lymphoblastic leukemia.** *Cancer research*
Duque-Afonso, J., Lin, C., Han, K., Morgens, D. W., Jeng, E. E., Weng, Z., Jeong, J., Wong, S. H., Zhu, L., Wei, M. C., Chae, H., Schrappe, M., Cario, et al
2018
- **Perspective on Diamond-Blackfan anemia: lessons from a rare congenital bone marrow failure syndrome** *LEUKEMIA*
Sakamoto, K. M., Narla, A.
2018; 32 (2): 249-51
- **Beyond mRNA: The role of non-coding RNAs in normal and aberrant hematopoiesis.** *Molecular genetics and metabolism*
Wilkes, M. C., Repellin, C. E., Sakamoto, K. M.
2017
- **Loss of FOXM1 promotes erythropoiesis through increased proliferation of erythroid progenitors.** *Haematologica*
Youn, M., Wang, N., LaVasseur, C., Bibikova, E., Kam, S., Glader, B., Sakamoto, K. M., Narla, A.
2017
- **A PET/MR Imaging Approach for the Integrated Assessment of Chemotherapy-induced Brain, Heart, and Bone Injuries in Pediatric Cancer Survivors: A Pilot Study.** *Radiology*
Theruvath, A. J., Ilivitzki, A., Muehe, A., Theruvath, J., Gulaka, P., Kim, C., Luna-Fineman, S., Sakamoto, K. M., Yeom, K. W., Yang, P., Moseley, M., Chan, F., Daldrup-Link, et al
2017: 170073
- **Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo.** *Journal of virology*
François, S., Sen, N., Mitton, B., Xiao, X., Sakamoto, K. M., Arvin, A.
2016; 90 (19): 8686-8697
- **Navigating your career path in pediatric hematology/oncology: On and off the beaten track.** *Pediatric blood & cancer*
Zweidler-McKay, P. A., Hogan, M. S., Jubran, R., Black, V., Casillas, J., Harper, J., Malempati, S., Margolin, J., Felgenhauer, J., Sakamoto, K. M., Franklin, J., Shah, M., Seibel, et al
2016; 63 (10): 1723-1730
- **CBP/p300 acetyltransferase activity in hematologic malignancies.** *Molecular genetics and metabolism*
Dutta, R., Tiu, B., Sakamoto, K. M.
2016; 119 (1-2): 37-43
- **The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia** *LEUKEMIA*
Huang, W., Luan, C., Hjort, E. E., Bei, L., Mishra, R., Sakamoto, K. M., Plataniias, L. C., Eklund, E. A.
2016; 30 (7): 1502-1509
- **A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure** *JOURNAL OF GENETICS AND GENOMICS*
Ear, J., Hsueh, J., Nguyen, M., Zhang, Q., Sung, V., Chopra, R., Sakamoto, K. M., Lin, S.
2016; 43 (5): 307-318
- **Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Klenk, C., Gawande, R., Tran, V. T., Leung, J. T., Chi, K., Owen, D., Luna-Fineman, S., Sakamoto, K. M., McMillan, A., Quon, A., Daldrup-Link, H. E.
2016; 57 (1): 70-77
- **Flow-induced protein kinase A-CREB pathway acts via BMP signaling to promote HSC emergence** *JOURNAL OF EXPERIMENTAL MEDICINE*
Kim, P. G., Nakano, H., Das, P. P., Chen, M. J., Rowe, R. G., Chou, S. S., Ross, S. J., Sakamoto, K. M., Zon, L. I., Schlaeger, T. M., Orkin, S. H., Nakano, A., Daley, et al
2015; 212 (5): 633-648

- **Targeting novel signaling pathways for resistant acute myeloid leukemia.** *Molecular genetics and metabolism*
Sakamoto, K. M., Grant, S., Saleiro, D., Crispino, J. D., Hijjiya, N., Giles, F., Plataniias, L., Eklund, E. A.
2015; 114 (3): 397-402
- **TNF-mediated inflammation represses GATA1 and activates p38 MAP kinase in RPS19-deficient hematopoietic progenitors.** *Blood*
Bibikova, E., Youn, M., Danilova, N., Ono-Uruga, Y., Konto-Ghiorgi, Y., Ochoa, R., Narla, A., Glader, B., Lin, S., Sakamoto, K. M.
2014; 124 (25): 3791-3798
- **Efficacy and Safety of Eculizumab in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria** *PEDIATRIC BLOOD & CANCER*
Reiss, U. M., Schwartz, J., Sakamoto, K. M., Puthenveetil, G., Ogawa, M., Bedrosian, C. L., Ware, R. E.
2014; 61 (9): 1544-1550
- **The role of the DNA damage response in zebrafish and cellular models of Diamond Blackfan anemia.** *Disease models & mechanisms*
Danilova, N., Bibikova, E., Covey, T. M., Nathanson, D., Dimitrova, E., Konto, Y., Lindgren, A., Glader, B., Radu, C. G., Sakamoto, K. M., Lin, S.
2014; 7 (7): 895-905
- **Letting microRNAs overcome resistance to chemotherapy in acute myeloid leukemia.** *Leukemia & lymphoma*
Sakamoto, K. M.
2014; 55 (7): 1449-1450
- **MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation.** *Haematologica*
Pigazzi, M., Manara, E., Bresolin, S., Tregnago, C., Beghin, A., Baron, E., Giarin, E., Cho, E., Masetti, R., Rao, D. S., Sakamoto, K. M., Basso, G.
2013; 98 (4): 602-610
- **Increased Abscess Formation and Defective Chemokine Regulation in CREB Transgenic Mice** *PLOS ONE*
Wen, A. Y., Landaw, E. M., Ochoa, R., Cho, M., Chao, A., Lawson, G., Sakamoto, K. M.
2013; 8 (2)
- **Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia** *BMC CANCER*
Chang, V. Y., Basso, G., Sakamoto, K. M., Nelson, S. F.
2013; 13
- **Activity of Egr-1 promoter induced by UV light in human primary dermal fibroblasts transduced with Ad-Egr-1/Luc is repressed by betamethasone.** *GENE THERAPY AND MOLECULAR BIOLOGY*
Martinez-Flores, F., Barrera-Lopez, A., Sandoval-Zamora, H. E., Garcia-Cavazos, R., Franco-Bourland, R. E., Madinaveitia-, J. A., Zentella-Dehesa, A., Curiel, D. T., Sakamoto, K.
2013; 15: 92-106
- **Sox4 cooperates with CREB in myeloid transformation** *BLOOD*
Sandoval, S., Kraus, C., Cho, E., Cho, M., Bies, J., Manara, E., Accordi, B., Landaw, E. M., Wolff, L., Pigazzi, M., Sakamoto, K. M.
2012; 120 (1): 155-165
- **The neutropenic diet... still ageless?** *Oncology (Williston Park, N.Y.)*
Aftandilian, C. C., Milotich, C., Sakamoto, K. M.
2012; 26 (6): 586-?
- **Editorial: Granulopoiesis versus monopoiesis: a consequence of transcription factors dancing with the right partners** *JOURNAL OF LEUKOCYTE BIOLOGY*
Sakamoto, K. M.
2011; 90 (4): 637-638
- **Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells** *LEUKEMIA & LYMPHOMA*
Aldana-Masangkay, G. I., Rodriguez-Gonzalez, A., Lin, T., Ikeda, A. K., Hsieh, Y., Kim, Y., Lomenick, B., Okemoto, K., Landaw, E. M., Wang, D., Mazitschek, R., Bradner, J. E., Sakamoto, et al
2011; 52 (8): 1544-1555
- **Increasing Diversity in Pediatric Hematology/Oncology** *PEDIATRIC BLOOD & CANCER*
Fruge, E., Lakoski, J. M., Luban, N., Lipton, J. M., Poplack, D. G., Hagey, A., Felgenhauer, J., Hilden, J., Margolin, J., Vaiselbuh, S. R., Sakamoto, K. M.
2011; 57 (1): 147-152

- **The Role of HDAC6 in Cancer** *JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY*
Aldana-Masangkay, G. I., Sakamoto, K. M.
2011
- **Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926** *PLOS ONE*
Lin, T. L., Wang, Q. H., Brown, P., Peacock, C., Merchant, A. A., Brennan, S., Jones, E., McGovern, K., Watkins, D. N., Sakamoto, K. M., Matsui, W.
2010; 5 (12)
- **The Role of the Transcription Factor CREB in Immune Function** *JOURNAL OF IMMUNOLOGY*
Wen, A. Y., Sakamoto, K. M., Miller, L. S.
2010; 185 (11): 6413-6419
- **Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia** *NATURE GENETICS*
Niemeyer, C. M., Kang, M. W., Shin, D. H., Furlan, I., Erlacher, M., Bunin, N. J., Bunda, S., Finklestein, J. Z., Sakamoto, K. M., Gorr, T. A., Mehta, P., Schmid, I., Kropshofer, et al
2010; 42 (9): 794-U93
- **Targeting CREB for Cancer Therapy: Friend or Foe** *CURRENT CANCER DRUG TARGETS*
Xiao, X., Li, B. X., Mitton, B., Ikeda, A., Sakamoto, K. M.
2010; 10 (4): 384-391
- **Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy** *DRUG RESISTANCE UPDATES*
Wu, W. K., Sakamoto, K. M., Milani, M., Aldana-Masangkay, G., Fan, D., Wu, K., Lee, C. W., Cho, C. H., Yu, J., Sung, J. J.
2010; 13 (3): 87-92
- **ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor beta and c-KIT Signaling Pathways** *MOLECULAR CANCER THERAPEUTICS*
Ikeda, A. K., Judelson, D. R., Federman, N., Glaser, K. B., Landaw, E. M., Denny, C. T., Sakamoto, K. M.
2010; 9 (3): 653-660
- **Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer** *ONCOGENE*
Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C. M., Deshaies, R. J., Sakamoto, K. M.
2008; 27 (57): 7201-7211
- **Role of the aggresome pathway in cancer: Targeting histone deacetylase 6-dependent protein degradation** *CANCER RESEARCH*
Rodriguez-Gonzalez, A., Lin, T., Ikeda, A. K., Sinnns-Waldrip, T., Fu, C., Sakamoto, K. M.
2008; 68 (8): 2557-2560
- **CREB is a critical regulator of normal hematopoiesis and leukemogenesis** *BLOOD*
Cheng, J. C., Kinjo, K., Judelson, D. R., Chang, J., Wu, W. S., Schmid, I., Shankar, D. B., Kasahara, N., Stripecke, R., Bhatia, R., Landaw, E. M., Sakamoto, K. M.
2008; 111 (3): 1182-1192
- **Expression profile of CREB knockdown in myeloid leukemia cells.** *BMC cancer*
Pellegrini, M., Cheng, J. C., Voutila, J., Judelson, D., Taylor, J., Nelson, S. F., Sakamoto, K. M.
2008; 8: 264-?
- **Cancer stem cells: The root of the problem** *PEDIATRIC RESEARCH*
Lin, T. L., Fu, C., Sakamoto, K. M.
2007; 62 (3): 239-239
- **Potential role of CREB as a prognostic marker in acute myeloid leukemia.** *Future oncology*
Cheng, J. C., Esparza, S., Sandoval, S., Shankar, D., Fu, C., Sakamoto, K. M.
2007; 3 (4): 475-480
- **PEG-asparaginase** *EXPERT OPINION ON PHARMACOTHERAPY*
Fu, C. H., Sakamoto, K. M.
2007; 8 (12): 1977-1984
- **ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia** *BLOOD*
Shankar, D. B., Li, J., Tapang, P., McCall, J. O., Pease, L. J., Dai, Y., Wei, R., Albert, D. H., Bouska, J. J., Osterling, D. J., Guo, J., Marcotte, P. A., Johnson, et al

2007; 109 (8): 3400-3408

- **Report on the workshop "New Technologies in Stem Cell Research," Society for Pediatric Research, San Francisco, California, April 29, 2006.** *Stem cells*
Cheng, J. C., Horwitz, E. M., Karsten, S. L., Shoemaker, L., Kornblum, H. I., Malik, P., Sakamoto, K. M.
2007; 25 (4): 1070-1088
- **Molecular targets and the treatment of myeloid leukemia** *MOLECULAR GENETICS AND METABOLISM*
Ikeda, A., Shankar, D. B., Watanabe, M., Tamanoi, F., Moore, T. B., Sakamoto, K. M.
2006; 88 (3): 216-224
- **Calcium-dependent upregulation of E4BP4 expression correlates with glucocorticoid-evoked apoptosis of human leukemic CEM cells** *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*
Priceman, S. J., Kirzner, J. D., Nary, L. J., Morris, D., Shankar, D. B., Sakamoto, K. M., Medh, R. D.
2006; 344 (2): 491-499
- **FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia** *STEM CELLS*
Parcells, B. W., Ikeda, A. K., Simms-Waldrip, T., Moore, T. B., Sakamoto, K. M.
2006; 24 (5): 1174-1184
- **Role of cyclic AMP response element binding protein in human leukemias** *CANCER*
Shankar, D. B., Cheng, J. C., Sakamoto, K. M.
2005; 104 (9): 1819-1824
- **The role of CREB as a proto-oncogene in hematopoiesis** *CELL CYCLE*
Kinjo, K., Sandoval, S., Sakamoto, K. M., Shankar, D. B.
2005; 4 (9): 1134-1135
- **Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.** *MedGenMed : Medscape general medicine*
Lasky, J., Sakamoto, K. M.
2005; 7 (1): 21-?
- **Topics in pediatric leukemia--Fanconi's anemia: new insights.** *MedGenMed : Medscape general medicine*
Federman, N., Sakamoto, K. M.
2005; 7 (2): 23-?
- **Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors.** *MedGenMed : Medscape general medicine*
Casillas, J., Sakamoto, K. M.
2005; 7 (1): 22-?
- **Topics in pediatric leukemia--acute lymphoblastic leukemia.** *MedGenMed : Medscape general medicine*
Esparza, S. D., Sakamoto, K. M.
2005; 7 (1): 23-?
- **Chimeric molecules to target proteins for ubiquitination and degradation** *UBIQUITIN AND PROTEIN DEGRADATION, PT B*
Sakamoto, K. M.
2005; 399: 833-?
- **Knocking down human disease: Potential uses of RNA interference in research and gene therapy** *PEDIATRIC RESEARCH*
Sakamoto, K. A.
2004; 55 (6): 912-913
- **Comparison of bone marrow aspirates and biopsies in pediatric patients with ALL at days 7 and 14 of induction therapy** *LEUKEMIA & LYMPHOMA*
Countouriotis, A., Landaw, E. M., Naeim, F., Moore, T. B., Sakamoto, K. M.
2004; 45 (4): 745-747
- **Chemical genetic control of protein levels: Selective in vivo targeted degradation** *JOURNAL OF THE AMERICAN CHEMICAL SOCIETY*
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., Crews, C. M.
2004; 126 (12): 3748-3754
- **BUBR1 deficiency results in abnormal megakaryopoiesis** *BLOOD*
Wang, Q., Liu, T. Y., Fang, Y. Q., Xie, S. Q., Huang, X., Mahmood, R., Ramaswamy, G., Sakamoto, K. M., Darzynkiewicz, Z., Xu, M., Dai, W.

2004; 103 (4): 1278-1285

- **The role of cyclic-AMP binding protein (CREB) in leukemia cell proliferation and acute leukemias** *LEUKEMIA & LYMPHOMA*
Shankar, D. B., Sakamoto, K. M.
2004; 45 (2): 265-270
- **Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter** *ANTICANCER RESEARCH*
Hsu, H., Rainov, N. G., QUINONES, A., Eling, D. J., Sakamoto, K. M., Spear, M. A.
2003; 23 (3B): 2723-2728
- **The role of p53CDC in cell cycle control and mammalian cell proliferation, differentiation, and apoptosis** *EXPERIMENTAL AND MOLECULAR PATHOLOGY*
Lin, M., Chang, J. K., Shankar, D., Sakamoto, K. M.
2003; 74 (2): 123-128
- **Fizzy-related RNA expression patterns in mammalian development and cell lines** *MOLECULAR GENETICS AND METABOLISM*
Mendoza, M. J., Wang, C. X., Lin, M., Braun, J., Sakamoto, K. M.
2002; 76 (4): 363-366
- **Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia** *BLOOD*
Crans-Vargas, H. N., Landaw, E. M., Bhatia, S., Sandusky, G., Moore, T. B., Sakamoto, K. M.
2002; 99 (7): 2617-2619
- **Bacterial peptidoglycan-induced tnfr-alpha transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kappa B** *JOURNAL OF IMMUNOLOGY*
Xu, Z. J., Dziarski, R., Wang, Q. L., Swartz, K., Sakamoto, K. M., Gupta, D.
2001; 167 (12): 6975-6982
- **p53CDC/hCDC20 is associated with BUBR1 and may be a downstream target of the spindle checkpoint kinase** *ONCOGENE*
Wu, H. Y., Lan, Z. D., Li, W. Q., WU, S. C., WEINSTEIN, J., Sakamoto, K. M., Dai, W.
2000; 19 (40): 4557-4562
- **Ubiquitin-mediated proteolysis and human disease** *MOLECULAR GENETICS AND METABOLISM*
Vu, P. K., Sakamoto, K. M.
2000; 71 (1-2): 261-266
- **Granulocyte colony-stimulating factor induces egr-1 up-regulation through interaction of serum response element-binding proteins** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Mora-Garcia, P., Sakamoto, K. M.
2000; 275 (29): 22418-22426
- **Stress-induced stimulation of early growth response gene-1 by p38/stress-activated protein kinase 2 is mediated by a cAMP-responsive promoter element in a MAPKAP kinase 2-independent manner** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Rolli, M., Kotlyarov, A., Sakamoto, K. M., Gaestel, M., Neininger, A.
1999; 274 (28): 19559-19564
- **Analysis of functional elements in the human Egr-1 gene promoter** *RHEUMATOLOGY INTERNATIONAL*
Aicher, W. K., Sakamoto, K. M., Hack, A., Eibel, H.
1999; 18 (5-6): 207-214
- **Analysis of cell death in myeloid cells inducibly expressing the cell cycle protein p53Cdc** *EXPERIMENTAL HEMATOLOGY*
Lin, M., Mendoza, M., Kane, L., WEINSTEIN, J., Sakamoto, K. M.
1998; 26 (10): 1000-1006
- **Genomic organization, 5' flanking enhancer region, and chromosomal assignment of the cell cycle gene, p53Cdc** *MOLECULAR GENETICS AND METABOLISM*
WEINSTEIN, J., Karim, J., Geschwind, D. H., Nelson, S. F., Krumm, J., Sakamoto, K. M.
1998; 64 (1): 52-57
- **Characterization of cis-acting sequences and trans-acting signals regulating early growth response 1 and c-fos promoters through the granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells** *BLOOD*

Watanabe, S., Kubota, H., Sakamoto, K. M., Arai, K.
1997; 89 (4): 1197-1206

● **The molecular mechanism of action of granulocyte-macrophage colony-stimulating factor** *JOURNAL OF INVESTIGATIVE MEDICINE*

Kwon, E. M., Sakamoto, K. M.
1996; 44 (8): 442-446

● **Regulation of egr-1 gene expression by retinoic acid in a human growth factor-dependent cell line** *INTERNATIONAL JOURNAL OF HEMATOLOGY*

Horie, M., Sakamoto, K. M., Broxmeyer, H. E.
1996; 63 (4): 303-309

● **THE BIOLOGY AND CLINICAL-APPLICATIONS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR** *SYMP DURING THE NATIONAL PEDIATRIC BLOOD CLUB PROGRAM OF THE AMERICAN PEDIATRIC SOC AND THE SOC OF PEDIATRIC RESEARCH : LYMPHOCYTES AND LYMPHOKINES IN HEALTH AND DISEASE*

Sakamoto, K. M., Golde, D. W., Gasson, J. C.
MOSBY-ELSEVIER.1991: S17-S20